The presence of CD169+ macrophages in lymph nodes draining different tumor types and their correlation with a better patient survival, their unique capacity to screen the lymphatic and blood circulation and, finally, their capacity to collaborate with DCs, all point to CD169+ macrophages as appealing targets for the design of anti-cancer vaccines. This evidence concerns the gene SIGLEC1 and cancer.